Ginkgo Bioworks Collaborated with Pfizer to Discover RNA-Based Drug Candidates
Shots:
- Ginkgo will receive an up front and is eligible to receive research fees, development, and commercial milestones of ~$331M across 3 programs along with royalties on sales
- The collaboration will use Ginkgo's RNA technology to advance the discovery & development of novel RNA molecules across priority research areas. The technology combines high-throughput screening of the behavior of RNA constructs with a multi-parameter design framework for the identification of novel natural and synthetic elements optimal for a particular application
- Pfizer will identify new RNA constructs that can improve stability & expression to create new therapies. Ginkgo aims to achieve efficient production, circularization, improved stability & enhanced translation of RNA constructs
Ref: PR Newswire | Image: Ginkgo
Related News:- Ginkgo Bioworks Collaborated with Wisconsin Alumni Research Foundation to Discover GD2 CAR T-Cell Therapies for Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
